RecruitingPhase 2NCT07033481

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

Sponsor

EIP Pharma Inc

Enrollment

20 participants

Start Date

Oct 2, 2025

Study Type

INTERVENTIONAL

Conditions

Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

Summary

The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.

Eligibility

Min Age: 40 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Neflamapimod and a drug called Placebo for people with nonfluent variant primary progressive aphasia (nfvppa). The study is currently recruiting participants at 7 locations. People eligible for this study include aged 40 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNeflamapimod

Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40 mg capsules

DRUGPlacebo

Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Locations(7)

Northwestern Memorial Hospital

Chicago, Illinois, United States

Mayo Clinic

Rochester, Minnesota, United States

Columbia University

New York, New York, United States

The Ohio State University

Columbus, Ohio, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Windsor Research Unit, Fulbourn Hospital

Cambridge, United Kingdom

Clinical Ageing Research Unit, Campus for Ageing and Vitality, Biomedical Research Building

Newcastle upon Tyne, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07033481

Related Trials

Intervention for Communication Quality of Life in Primary Progressive Aphasia

NCT072196801 location

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT0436368427 locations